|
|||||
|
Multiple Sclerosis Info
|
Wednesday, February 6
Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
by
multiplesclerosis
on Wed 06 Feb 2008 06:57 AM CST
Biogen Idec Inc. and PDL BioPharma, Inc. (PDL) announced
that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium- enhancing lesions when daclizumab more »
Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
by
multiplesclerosis
on Wed 06 Feb 2008 01:00 AM CST
To prospectively evaluate predictors of incomplete recovery after the first attacks in a cohort of patients with clinically isolated syndrome or relapsing-remitting multiple sclerosis. more »
|
||||
